Sign up to save your podcasts
Or
Share Dr John Campbell - Definitive vaccine myocarditis paper
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Dr John Campbell - Definitive vaccine myocarditis paper
May 8, 2025
We urge governments to remove the COVID-19 mRNA products from the market,
due to the well-documented risk of myocardial damage, a risk that is strongest for younger males ( under 40 years old).
Independent Medical Alliance
https://imahealth.org
Senior Fellow of Paediatric Cardiology, Dr. Kirk Milhoan
National News desk link
https://www.youtube.com/watch?v=iAdYo0EJvkU
Myocarditis after SARS-CoV-2 infection and COVID-19 vaccination: Epidemiology, outcomes, and new perspectives
International Journal of Cardiovascular Research & Innovation (OPEN ACCESS)
https://cardiovascular-research-and-innovation.reseaprojournals.com/Articles/myocarditis-after-sars-cov-2-infection-and-covid-19-vaccination-epidemiology-outcomes-and-new-perspectives
Myocarditis, typically manifesting as myopericarditis,
is among the serious cardiac consequences observed over the course of the COVID-19 pandemic.
A comprehensive, evidence-based literature synthesis
Clinical trial data reanalyses
Post-marketing surveillance
Large observational studies
Epidemiological, clinical, and immunological perspectives
Phenomenon of myocarditis post SARS-CoV-2 infection versus COVID-19 vaccine-induced myocarditis.
Conclusions refute several claims
(1). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Omicron infections have caused more cases of myocarditis than the COVID-19 mRNA immunizations
Refuted
(2) mRNA vaccine-induced myocarditis is typically mild, transient, and rare, with no long-term sequelae
Refuted
(3) the risk-benefit calculus favors continued use of these products despite evidence of more iatrogenic (vaccine causes) cases
Refuted
View all episodes
By May 8, 2025
We urge governments to remove the COVID-19 mRNA products from the market,
due to the well-documented risk of myocardial damage, a risk that is strongest for younger males ( under 40 years old).
Independent Medical Alliance
https://imahealth.org
Senior Fellow of Paediatric Cardiology, Dr. Kirk Milhoan
National News desk link
https://www.youtube.com/watch?v=iAdYo0EJvkU
Myocarditis after SARS-CoV-2 infection and COVID-19 vaccination: Epidemiology, outcomes, and new perspectives
International Journal of Cardiovascular Research & Innovation (OPEN ACCESS)
https://cardiovascular-research-and-innovation.reseaprojournals.com/Articles/myocarditis-after-sars-cov-2-infection-and-covid-19-vaccination-epidemiology-outcomes-and-new-perspectives
Myocarditis, typically manifesting as myopericarditis,
is among the serious cardiac consequences observed over the course of the COVID-19 pandemic.
A comprehensive, evidence-based literature synthesis
Clinical trial data reanalyses
Post-marketing surveillance
Large observational studies
Epidemiological, clinical, and immunological perspectives
Phenomenon of myocarditis post SARS-CoV-2 infection versus COVID-19 vaccine-induced myocarditis.
Conclusions refute several claims
(1). Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Omicron infections have caused more cases of myocarditis than the COVID-19 mRNA immunizations
Refuted
(2) mRNA vaccine-induced myocarditis is typically mild, transient, and rare, with no long-term sequelae
Refuted
(3) the risk-benefit calculus favors continued use of these products despite evidence of more iatrogenic (vaccine causes) cases
Refuted